Facts and public policy: Should i keep my child on ADHD drugs?

Journal of Clinical Psychopharmacology

Volumn 26, Issue 3, 2006, Pages 223-224

  Shader, Richard I ^a   Oesterheld, Jessica R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; EPHEDRINE; METHYLPHENIDATE; PHENYLPROPANOLAMINE;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; PRIORITY JOURNAL; SUDDEN DEATH;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEATH, SUDDEN, CARDIAC; HUMANS; PARENTS; PSYCHOTROPIC DRUGS; SYMPATHOMIMETICS;

EID: 33744497821     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000225814.94.999.7d     Document Type: Editorial

References (13)

1. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1447.
2. Food and Drug Administration. Drug Safety and Advisory Committee Meeting. February 9 and 10, 2006: table of contents. Available at: www.fda.gov/ohms/ dockets/ac/06/briefing/2006-4202_00_TOC.htm. Accessed April 21, 2006.
3. Friedman RA. The changing face of teenage drug abuse - the trend toward prescription drugs. N Engl J Med. 2006;354:1448-1450.
4. Food and Drug Administration. Available at: http://www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4210b_05_01_AdderallSafetyReview.pdf. Accessed April 21, 2006.
5. Xander HT, Wehrens MD, Vos MA, et al. Novel insights in the congenital long QT syndrome. Ann Intern Med. 2002;137:981-992.
6. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66:253-259.
7. Safer DJ. Relative cardiovascular safety of psychostimulants use to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1992;2:279-290.
8. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry. 2001;40:525-529.
9. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42:424-433.
10. Stein MA, Sarampote CS, Waldman ID. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404. Accessed March 22, 2006 [PubMed].
11. Aman MG, Werry JS. The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of action. Psychopharmacologia. 1975;43:163-168.
12. Stowe CD, Gardner SF, Gist CC, et al. 24-Hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother. 2002;36:1142-1149.
13. Samuels JA, Franco K, Wan F, et al. Effect of stimulants on 24-hour ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92-95.